RBC Capital Reiterates Outperform Rating and $42 PT on Teva Pharmaceuticals (TEVA) Following 4Q Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
Teva Pharma (TEVA) PT Lowered to $40 at Maxim Group
February 13, 2017 1:14 PM ESTMaxim Group lowered its price target on Teva Pharma (NYSE: TEVA) to $40.00 (from $41.00) while maintaining a Hold rating following results this morning.
Analyst Gabrielle Zhou commented, "This morning, Teva reported 4Q16 and full year results; total quarterly revenues were $6.5B, up 16.7% sequentially. Revenues... More
Teva Pharma (TEVA) Tops Q4 EPS by 2c; Reaffirms
February 13, 2017 6:43 AM EST(Updated - February 13, 2017 6:44 AM EST)
Teva Pharma (NYSE: TEVA) reported Q4 EPS of $1.38, $0.02 better than the analyst estimate of $1.36. Revenue for the quarter came in at $6.5 billion versus the consensus estimate of $6.26 billion.
Teva reaffirms its 2017 full year non-GAAP guidance; including revenues of $23.8 - 24.5 billion, and non-GAAP EPS of $4.90 - 5.30
"2016 was a transitional year for Teva - one that... More
